Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor
暂无分享,去创建一个
Dahlia R. Weiss | B. Shoichet | Joanne Baltos | P. Sexton | A. Christopoulos | L. May | A. Kruse | R. Sunahara | B. Kobilka | Weijiao Huang | Hayarpi Torosyan | C. Valant | Ee Von Moo | M. Clark | Sabine Albold | M. Korczynska | Jun Xu | B. Lyda
[1] Ruben Abagyan,et al. Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor , 2016, Cell Research.
[2] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.
[3] Ali Jazayeri,et al. Intracellular allosteric antagonism of the CCR9 receptor , 2016, Nature.
[4] P. Sexton,et al. Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects , 2012, Molecular Pharmacology.
[5] A. Grover. Use of Allosteric Targets in the Discovery of Safer Drugs , 2013, Medical Principles and Practice.
[6] N. Birdsall,et al. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. , 1998, Pharmacological reviews.
[7] Jesús Giraldo,et al. Helix 3 acts as a conformational hinge in Class A GPCR activation: An analysis of interhelical interaction energies in crystal structures. , 2015, Journal of structural biology.
[8] F. Mitchelson,et al. THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.
[9] Jan Jakubík,et al. Allosteric Modulation of Muscarinic Acetylcholine Receptors , 2010, Pharmaceuticals.
[10] H. Colecraft,et al. Signaling Mechanisms Underlying Muscarinic Receptor-mediated Increase in Contraction Rate in Cultured Heart Cells* , 1998, The Journal of Biological Chemistry.
[11] Gareth J Waldron,et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.
[12] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[13] Tudor I. Oprea,et al. Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..
[14] Gregory W. Kauffman,et al. Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects. , 2016, Journal of medicinal chemistry.
[15] S. P. Andrews,et al. Extra-helical binding site of a glucagon receptor antagonist , 2016, Nature.
[16] Arthur Christopoulos,et al. Novel Allosteric Modulators of G Protein-coupled Receptors* , 2015, The Journal of Biological Chemistry.
[17] Brian K. Shoichet,et al. Ligand Pose and Orientational Sampling in Molecular Docking , 2013, PloS one.
[18] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[19] I. Kuntz,et al. Automated docking with grid‐based energy evaluation , 1992 .
[20] Henry Lin,et al. Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.
[21] J M Blaney,et al. A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.
[22] P. Conn,et al. Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders , 2017, Neuron.
[23] J. Wess,et al. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss , 2016, The Journal of clinical investigation.
[24] Jonathan A. Javitch,et al. Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening , 2013, J. Chem. Inf. Model..
[25] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[26] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[27] Peter A. Kollman,et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .
[28] E. El-Fakahany,et al. The allosteric binding profile of himbacine: a comparison with other cardioselective muscarinic antagonists. , 1990, European journal of pharmacology.
[29] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[30] Nathan Robertson,et al. Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .
[31] R. Duman,et al. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. , 2016, Drug discovery today.
[32] Ruben Abagyan,et al. Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists , 2016, Nature.
[33] A. Christopoulos,et al. Characterization of the Novel Positive Allosteric Modulator, LY2119620, at the Muscarinic M2 and M4 Receptors , 2014, Molecular Pharmacology.
[34] Hualiang Jiang,et al. Two disparate ligand-binding sites in the human P2Y1 receptor , 2015, Nature.
[35] C. Lindsley,et al. Development of a Highly Potent, Novel M5 Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1H-Indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380) , 2014, Journal of medicinal chemistry.
[36] J. Wess,et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.
[37] J. Andrew McCammon,et al. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor , 2016, Proceedings of the National Academy of Sciences.
[38] Gregory D. Hawkins,et al. Extension of the platform of applicability of the SM5.42R universal solvation model , 1999 .
[39] Maria F. Sassano,et al. Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor , 2013, ACS chemical biology.
[40] D. Price,et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? , 2014, npj Primary Care Respiratory Medicine.
[41] M. Chancellor,et al. Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity , 2011, International Urogynecology Journal.
[42] B. Shoichet,et al. Hierarchical docking of databases of multiple ligand conformations. , 2005, Current topics in medicinal chemistry.
[43] K. Sharp,et al. Electrostatic contributions to heat capacity changes of DNA-ligand binding. , 1998, Biophysical journal.
[44] Patrik Johansson,et al. Structural insight into allosteric modulation of protease-activated receptor 2 , 2017, Nature.
[45] Jing Liu,et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2 , 2016, Nature chemical biology.
[46] Andreas Plückthun,et al. Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries. , 2017, ACS chemical biology.
[47] Michael M. Mysinger,et al. Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.
[48] Arthur Christopoulos,et al. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors , 2016, Nature.
[49] J. Irwin,et al. An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.
[50] K. Mohr,et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. , 2003, Molecular pharmacology.
[51] R. Cumming. Drugs affecting the autonomic nervous system. , 1951, Arizona medicine.
[52] Chris de Graaf,et al. Function-specific virtual screening for GPCR ligands using a combined scoring method , 2016, Scientific Reports.
[53] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[54] J. Richardson,et al. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. , 1999, Journal of molecular biology.
[55] H. Hasselmann. Scopolamine and depression: a role for muscarinic antagonism? , 2014, CNS & neurological disorders drug targets.
[56] Albert C. Pan,et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.
[57] Albert C. Pan,et al. Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.
[58] R. Read,et al. Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures , 2017, Current molecular pharmacology.
[59] K. Andersson. Antimuscarinics for treatment of overactive bladder , 2004, The Lancet Neurology.
[60] O. Wassermann,et al. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. , 1969, European journal of pharmacology.
[61] J. Ellis,et al. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.
[62] Xin Chen,et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65 , 2015, Nature.
[63] Sujata Sharma,et al. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40 , 2017, Nature Structural &Molecular Biology.
[64] A. Kruse,et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.
[65] J. Irwin,et al. Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.
[66] P. Sexton,et al. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. , 2012, Endocrinology.
[67] M. Yamada,et al. Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice , 2003, Neuropharmacology.
[68] Brian K. Shoichet,et al. Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..
[69] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[70] Kim A. Sharp,et al. Polyelectrolyte electrostatics: Salt dependence, entropic, and enthalpic contributions to free energy in the nonlinear Poisson–Boltzmann model , 1995 .
[71] B. Shoichet,et al. Colloidal aggregation and the in vitro activity of traditional Chinese medicines. , 2015, ACS chemical biology.
[72] Arthur Christopoulos,et al. Advances in G Protein-Coupled Receptor Allostery: From Function to Structure , 2014, Molecular Pharmacology.
[73] S. Grzesiek,et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.
[74] B. Matthews,et al. A model binding site for testing scoring functions in molecular docking. , 2002, Journal of molecular biology.
[75] R. E. Higgs,et al. M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[76] Arthur Christopoulos,et al. A kinetic view of GPCR allostery and biased agonism. , 2017, Nature chemical biology.
[77] J. Kavanagh,et al. Anticholinergic activity in the nervous system: Consequences for visuomotor function , 2017, Physiology & Behavior.
[78] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[79] F. Schmäl,et al. Neuronal Mechanisms and the Treatment of Motion Sickness , 2013, Pharmacology.